Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study

Liangliang Ren · Ling Li · Lei Zhang · Xin Li · Xiaorui Fu · Xinhua Wang · Jingjing Wu · Zhenchang Sun · Xiaoyan Feng · Yu Chang · Zhiyuan Zhou · Feifei Nan · Jiaqin Yan · Fei Kong · Mingzhi Zhang

Received: 19 November 2020 / Accepted: 27 March 2021 / Published online: 12 April 2021
© The Author(s) 2021

Abstract Limited treatment options are available for relapsed or refractory diffuse large B cell lymphoma (RR DLBCL). Few clinical studies have reported the use of Ibrutinib, a covalent Bruton Tyrosine kinase (BTK) inhibitor, in RR DLBCL. There are relatively few clinical studies about Ibrutinib in RR DLBCL now. We retrospectively investigated the safety and efficacy of Ibrutinib (alone or in combination with other drugs) in patients with RR DLBCL. We reviewed the medical records of 40 RR DLBCL patients who received Ibrutinib alone or in combination with other drugs in our hospital from June 2018 to August 2020. The objective response rate (ORR) of RR DLBCL patients on Ibrutinib was 22.5%. The median progression free survival time (PFS) was 13.0 months (95% CI 8.914–17.086), and the median overall survival time (OS) was 15.0 months (95% CI 11.931–18.089). Rash (25.0%) and fatigue (25.0%) were the most common adverse reactions in this study. The application of Ibrutinib to patients with RR DLBCL has good short-term efficacy, and the adverse reactions are well tolerated. Combined treatment of Ibrutinib with other drugs has been found to be more effective than Ibrutinib therapy alone.

Keywords Ibrutinib · Relapsed or refractory diffuse large B-cell lymphoma · Efficacy · Safety

Springer
Introduction

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma (NHL) worldwide, accounting for 25% of all cases [1, 2]. Due to heterogeneity in morphology, biological, clinical characteristics and immunophenotype, prognosis of DLBCL varies, resulting in differences in survival rates [3, 4]. Based on gene profiling, DLBCL can be further classified as activated B-cell-like lymphoma (ABC), germinal center B-cell-like lymphoma (GCB) and primary mediastinal B-cell lymphoma [5].

Most patients of DLBCL achieve complete remission (CR) after treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), which is the current standard first-line treatment [6]. The 5-year survival rate after R-CHOP is 50% [7]. One third of DLBCL patients either do not respond to first line treatment or relapse and studies have shown the median survival of these patients to 4–6 months [8, 9]. Patients with RR DLBCL eligible for chemotherapy are salvaged with second line regimens such as ifosfamide, carboplatin, etoposide (ICE); dexamethasone, cytarabine and cisplatin (DHAP), etoposide, cytarabine, cisplatinum and methyl-prednisolone (ESHAP), gemcitabine, dexamethasone, and cisplatin (GDP). However, the long-term survival rate is less than 10%, and most patients die within 2 years [10]. High-dose chemotherapy plus autologous or allogeneic stem cell transplantation (SCT) remains the standard treatment regimen for young, with non-comorbid RR DLBCL patients [11]. Patients who did not respond to standard chemotherapy or relapsed after SCT are known to have poor prognosis. Anti-CD19 Chimeric antigen receptor T-cell therapy (CAR-T) has shown impressive activity in relapsed or refractory lymphoma, with sustained complete remission for 2 years in RR DLBCL [12]. CAR-T is associated with potentially fatal toxicities, including cytokine release syndrome and neurotoxicity making it ineligible for comorbid or older RR DLBCL with complications [13, 14]. Therefore, treatment of RR DLBCL patients of older age or with comorbid conditions remain challenging [8, 15].

Bruton’s Tyrosine kinase inhibitor (BTK) Ibrutinib is highly effective against a variety of B-cell malignancies [16]. Ibrutinib is a potent, irreversible and effective inhibitor of BTK that is taken orally, and was approved for indications in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) in 2013 and 2014 [17–19].

At present, there are relatively few clinical research about Ibrutinib in RR DLBCL. Therefore, this study used a retrospective study to evaluate the efficacy and safety of Ibrutinib in 40 patients with RR DLBCL.

Material and Methods

We reviewed 40 patients with RR DLBCL who were treated with Ibrutinib (or combined with other drugs) in the First Affiliated Hospital of Zhengzhou University from June 2018 to August 2020 (median age, 61 years; median follow up, 11.5 months). The 40 patients were divided into the Ibrutinib ± R group and Ibrutinib + lenalidomide ± R group. To details about the Ibrutinib regimen given to RR DLBCL patients is shown in Fig. 1 and the baseline characteristics is shown in Table 1.

Inclusion and Exclusion Criteria

Inclusion criteria: The histopathological type of the primary lesions was confirmed as DLBCL by two senior pathologists; Failure or relapse after treatment with standard second-line or above; Patients with at least one measurable lesion; Age over 18 years old; Have not previously received BTK inhibitor treatment. Exclusion criteria: Pregnant and lactating women; Accompanied by severe organ damage or failure.

Study Design

This study aimed to evaluate the effectiveness and safety of Ibrutinib in the treatment of 40 patients with RR DLBCL. All patients received Ibrutinib orally for more than one month. They received Ibrutinib orally, 140 mg × 4 tablets, a total dose of 560 mg one day, until disease progression or death. In case of intolerance to Ibrutinib, either the dose was reduced to 420 mg per day or was withheld for a maximum of one week. Treatment with Ibrutinib for 21 days was considered as one cycle of treatment and efficacy evaluation was performed after every 2 cycles of treatment. Efficacy assessment was done on the basis of physical examination, Eastern Cooperative Oncology
Group (ECOG) status assessment, bone marrow aspiration and biopsy (if bone marrow involved), radiologic examination using color Doppler ultrasonography and enhanced computed tomography (CT) or positron emission tomography-computed tomography (PET-CT) of involved organs.

Table 1 Baseline characteristics

| Clinical features | Ibrutinib ± R (%) (n = 27) | Ibrutinib + lenalidomide ± R (%) (n = 13) |
|-------------------|-----------------------------|------------------------------------------|
| The general informations |                             |                                          |
| Gender            |                             |                                          |
| Male              | 15 (55.6)                   | 7 (53.8)                                 |
| Female            | 12 (44.4)                   | 6 (46.2)                                 |
| Age (year)        |                             |                                          |
| > 60              | 14 (51.9)                   | 7 (53.8)                                 |
| ≤ 60              | 13 (48.1)                   | 6 (46.2)                                 |
| ECOG              |                             |                                          |
| < 2               | 13 (48.1)                   | 8 (61.5)                                 |
| ≥ 2               | 14 (51.9)                   | 5 (38.5)                                 |
| Pathological characteristics |                  |                                          |
| EBER               |                             |                                          |
| Negative          | 23 (85.2)                   | 12 (92.3)                                |
| Positive          | 4 (14.8)                    | 1 (7.7)                                  |
| Ki-67              |                             |                                          |
| < 50%             | 1 (3.7)                     | 2 (15.4)                                 |
| ≥ 50%             | 26 (96.3)                   | 11 (84.6)                                |
| COO subtype       |                             |                                          |
| GCB               | 1 (3.7)                     | 2 (15.4)                                 |
| Non-GCB           | 26 (96.3)                   | 11 (84.6)                                |
| Ann Arbor stage   |                             |                                          |
| I–II              | 3 (11.1)                    | 2 (15.4)                                 |
| III–IV            | 24 (88.9)                   | 11 (84.6)                                |
| Previous chemotherapy |                         |                                          |
| ≤ 2               | 7 (26.0)                    | 3 (23.1)                                 |
| > 2               | 20 (74.0)                   | 10 (76.9)                                |
| IPI score         |                             |                                          |
| ≤ 3               | 14 (51.9)                   | 11 (84.6)                                |
| > 3               | 13 (48.1)                   | 2 (15.4)                                 |
| Extranodal sites  |                             |                                          |
| ≤ 1               | 10 (37.0)                   | 6 (46.2)                                 |
| > 1               | 17 (63.0)                   | 7 (53.8)                                 |
| Laboratory examinations |                  |                                          |
| LDH               |                             |                                          |
| Normal            | 9 (33.3)                    | 8 (61.5)                                 |
| Increased         | 18 (66.7)                   | 5 (38.5)                                 |
| Serum β2 microglobulin |             |                                          |
| Normal            | 22 (81.5)                   | 5 (38.5)                                 |
| Increased         | 5 (18.5)                    | 8 (61.5)                                 |
| Disease characteristics |                |                                          |
| B symptoms        |                             |                                          |
| Absent            | 19 (70.4)                   | 6 (46.2)                                 |
| Present           | 8 (29.6)                    | 7 (53.8)                                 |

COO cell of origin, GCB germinal centre B-cell, IPI international prognostic index, LDH lactate dehydrogenase
We retrospectively evaluated efficacy and safety of Ibrutinib in 40 patients with RR DLBCL. Twenty-seven patients received Ibrutinib ± R regimen. Rituximab was added with Ibrutinib in patients who have received 8 cycles of rituximab during previous lines of treatment. There are thirteen patients received Ibrutinib ± lenalidomide ± R. They received 10 mg of lenalidomide orally every day, and lenalidomide was taken for 2 weeks and stopped for 1 week. The application principles of Ibrutinib and rituximab are also stated above.

Assessments

Twenty-one days is one treatment cycle. Efficacy is evaluated every 2 cycles. According to WHO criteria, it is divided into: complete remission (CR); partial remission (PR), stable disease (SD), and progressive disease (PD). Objective response rate (ORR) = (CR + PR)/(CR + PR + SD + PD) × 100%, refers to the proportion of patients whose tumors have shrunk to a certain amount and maintained for a certain period of time. CR is defined as complete disappearance of the lesion. PR is defined as a reduction in lesion volume of more than half and no new lesions. PD is defined as lesions that has increased in volume by more than 25% or are new. SD is between PD and PR.

The long-term efficacy assessment indexes are: progression-free survival (PFS) and overall survival (OS). PFS refers to the time from the first administration of Ibrutinib until disease progression or death. OS is the time from the first administration of Ibrutinib to death from any cause or the last follow-up.

SPSS 24.0 statistical software was used for data processing, analysis and relevant statistical chart drawing. Kaplan–Meier method was used to draw the survival curve, and Cox proportional hazard regression model was used to analyze the factors affecting PFS and OS of patients with RR DLBCL. $P < 0.05$ indicates that the difference is statistically significant.

Results

Short-Term Efficacy

The data collection cut-off time for the primary analysis was August 2020. Six patients (15.0%) had achieved CR, with three cases of PR (7.5%) and ten cases (25.0%) of SD. Nine of the forty (22.5%) patients had achieved ORR. In particular, ten of them were in Ibrutinib + lenalidomide + R group, CR was 40%, PR was 20%. Its ORR reached 60.0%. The specific follow-up results are shown in Fig. 2.

Long-Term Efficacy

For 40 patients with RR DLBCL, the median PFS was 13 months (95% CI 8.914–17.086) and the median OS was 15 months (95% CI 11.931–18.069). In Ibrutinib ± R group, the median PFS was 13 months (95% CI 8.411–17.589) and the median OS was 14 months (95% CI 10.286–17.714). The median PFS and the median OS in Ibrutinib + lenalidomide ± R group did not reach. Kaplan–Meier estimates graph of PFS and OS are shown in Fig. 3. Three patients in our cohort did not respond to multiple lines of treatment and were considered as primary refractory patients. These patients did not respond to Ibrutinib ± chemotherapy. The short-term efficacy and long-term efficacy results of the 3 patients are shown in Table 2.

Assessment of Adverse Events

In this study, Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE Version 5.0) was used to assess adverse events, which was used by the US National Institutes of Health in 2017 [20, 21]. The grade of adverse events was 1–5. No Grade 5 appeared in this study (Grade 5 means death).

Fig. 2 A stacked column of efficacy evaluation
We observed mild adverse events (Grade 1–2). In Ibrutinib ± R group, rash (8 patients, 29.6%) and inappetence (6 patients, 22.2%) were the most common adverse events. And in Ibrutinib + lenalidomide ± R group, the most common adverse events were nausea (4 patients, 30.8%) and fatigue (3 patients, 23.1%). In Ibrutinib ± R group, one patient developed severe urine tract bleeding for which Ibrutinib was discontinued and managed with haemostatic drugs and blood products. After 3 days, bleeding was controlled and the patient remained under observation for next 2 days. Under supervision, the patient was rechallenged with Ibrutinib and it was well tolerated thereafter. Two patients experienced severe fatigue, which was managed by reducing dose of Ibrutinib to 420 mg/day. Major treatment related adverse events for each treatment group were reported in Table 3. None of the patient developed hypertension.

**Table 2** Data of primary drug-resistant patients

| Patient ID | Short-term efficacy | Long-term efficacy | Regimens       |
|------------|---------------------|--------------------|----------------|
|            |                     | PFS (months) | OS (months)   |
| 1          | PD                  | 5               | 6              | Ibrutinib + R |
| 2          | PD                  | 1.5             | 2.5            | Ibrutinib + R + lenalidomide |
| 3          | PD                  | 5               | 6              | Ibrutinib + R |

**Fig. 3** A Ibrutinib ± R, Kaplan–Meier graph for progression-free survival (n = 27); B Ibrutinib ± R, Kaplan–Meier graph for overall survival (n = 27); C Ibrutinib + lenalidomide ± R, Kaplan–Meier graph for progression-free survival (n = 13); D Ibrutinib + lenalidomide ± R, Kaplan–Meier graph for overall survival (n = 13)
Analysis of Prognostic Factors

Cox proportional hazard regression model analyzed the factors affecting PFS and OS in 40 patients in this study. The results showed that ECOG score and COO subtype were significantly correlated with PFS and OS (HR and $P$ value are in Tables 4 and 5). Patients with ECOG PS $\leq 2$ or non-GCB DLBCL were found to have better PFS and OS. $P$ value $< 0.05$ was considered statistically significant.

Discussion

In recent years, Ibrutinib has been found to have strong antitumor activity in different B-cell malignancies [22]. Kelu Hou [7] conducted a meta-analysis of Ibrutinib therapy and reported overall response and CR as 49.7% and 27.7% respectively in RR DLBCL. Studies have shown that when Ibrutinib is combined with lenalidomide, the activity of DLBCL model increases, especially in non-germinal center B-cell-like (non-GCB) even in ABC DLBCL, which is consistent with BCR and MYD 88 signaling pathway [23]. It is suggested that clinical efficacy usually benefits from combination therapy compared with monotherapy. In addition, molecular analysis showed that patients with both MYD88 and CD79B mutations were the most sensitive to Ibrutinib [24]. Because of the short duration of this study and the limited number of specimens, genetic testing was not performed on it. This study will be gradually improved in subsequent studies. In this study, only 6 patients received Ibrutinib alone, including 1 patient achieved CR (15.0%), 4 patients achieved SD (10.0%) and 1 patient achieved PD (15.0%). This result makes us think about the resistance of Ibrutinib. In clinical practice, intrinsic and acquired resistance to Ibrutinib has indeed been observed.

The main adverse reactions in this study were grade 1–2, and grade 3–4 were relatively rare. Common adverse reactions were tolerable. For rare grade 3–4 adverse reactions, they could be recovered after stopping the drug for less than 1 week and symptomatic treatment was actively conducted. Paydas [25] mentioned that in early clinical trials, BTK inhibitors have been reported to be associated with increased rates of bleeding, including subdural hematoma, gastrointestinal bleeding and hematuria. However, the effect of BTK inhibitors on platelet function and bleeding risk is unclear. On the one hand, the dosage of Ibrutinib can be reduced. On the other hand, the indications and dosage of antithrombotic drugs are also important, and platelet transfusion should be considered even if there is no thrombocytopenia in the case of severe bleeding [26]. Salem [27] noted that Ibrutinib can induce cardiovascular events, and cardiovascular toxicity is the leading cause of death. He found that Ibrutinib was associated with supraventricular arrhythmias (atrial fibrillation is the most common form), heart failure, ventricular arrhythmias, and conduction disorders. Brown [28] analyzed the data of 1505 patients treated with Ibrutinib and found that the previous history of atrial fibrillation and the age more than 65 years olds were independent risk factors for the occurrence of atrial fibrillation. In the end, it was concluded that atrial fibrillation occurred during the application of Ibrutinib is usually controllable without stopping the drug. Fortunately, Ibrutinib-induced arrhythmias (especially atrial fibrillation) were less likely to occur in this study and may be related to drug interactions and drug dosage. Tilly Varughese [29] analyzed the risk of severe infection in patients with lymphoma treated with Ibrutinib. For patients

### Table 3 Major treatment-related adverse events

| Adverse events              | Ibrutinib ± R (%) | Ibrutinib + lenalidomide ± R (%) |
|-----------------------------|-------------------|---------------------------------|
|                             | Grade 1/2 Grade 3/4 | Grade 1/2 Grade 3/4 |
| Fatigue                     | 5 (18.5) 1 (3.7)   | 3 (23.1) 1 (11.1) |
| Nausea                      | 4 (14.8) 0         | 4 (30.8) 0 |
| Vomiting                    | 3 (11.1) 0         | 1 (7.7) 0 |
| Inappetence                 | 6 (22.2) 0         | 2 (15.4) 0 |
| Diarrhea                    | 4 (14.8) 0         | 2 (15.4) 0 |
| Rash                        | 8 (29.6) 1 (3.7)   | 1 (7.7) 0 |
| Anemia                      | 3 (11.1) 0         | 2 (15.4) 0 |
| Neutropenia                 | 5 (18.5) 0         | 2 (15.4) 0 |
| Hemorrhage                  | 2 (7.4) 1 (3.7)    | 0 0 |
| Atrial fibrillation         | 3 (11.1) 0         | 1 (7.7) 0 |
| Respiratory tract infection | 1 (3.7) 0          | 0 0 |
| Arthralgia                  | 1 (3.7) 0          | 1 (7.7) 0 |
| Cough                       | 1 (3.7) 0          | 0 0 |
with lymphoma treated with Ibrutinib, he proposed that aggressive fungal infections were related to the use of corticosteroids at any time and to receive 3 previous anti-tumor regimens. The only factor associated with bacterial infection was the reduction of neutrophils. Therefore, the situation of infection should be closely monitored during the medication and targeted preventive measures should be taken actively. As the oral dose of Ibrutinib increases, the risk of hypertension will increase, and the incidence of grade III hypertension may be as high as 25% [25].

Seongseok Yun [30] proposed that patients with a tendency to worsen hypertension during treatment with Ibrutinib may also have an increased risk of atrial fibrillation. No patients with hypertension were found in this study. It may be related to the fact that 40 patients did not have hypertension before. Blood pressure and heart rate should be detected before and after the application of Ibrutinib, and antihypertensive drugs should be given in time. Diarrhea is a common side effect of Ibrutinib treatment, but its severity is not high, and it is a self-limited disease. It most often occurs in the first six months of treatment, with a median duration of 20 days [25].

Among the 40 patients in this study, CR was 15.0%, PR was 7.5%, SD was 25.0%, 9 patients achieved ORR (22.5%). But for patients with RR DLBCL: (1) About 30% of DLBCL patients will have recurrence, and the prognosis of patients who relapse after first-line treatment is extremely poor [31]; (2) The treatment options for refractory DLBCL are limited. In this study, CR and PR were lower after the treatment with Ibrutinib. But the long-term stability of RR DLBCL could be regarded as another therapeutic direction, and the short-term efficacy was acceptable. It also shows that our current plan still has defects.

In 2019, Andre Goy [32] initiated a clinical trial related to “Ibrutinib + lenalidomide + R in RR DLBCL”.

| Table 4 | Analysis of prognostic factors affecting PFS | Various | Univariate analysis | Multivariate analysis |
| --- | --- | --- | --- | --- |
| | | HR (95% CI) | P | HR (95% CI) | P |
| Gender | 0737 (0.316–1.717) | 0.480 | – | – |
| age | 0.473 (0.203–1.103) | 0.083 | – | – |
| ECOG | 4.516 (1.522–13.400) | 0.007 | 4.213 (1.410–12.585) | 0.010 |
| Ki-67 | 1.515 (0.201–11.394) | 0.687 | – | – |
| COO subtype | 0.172 (0.047–0.626) | 0.008 | 0.221 (0.061–0.803) | 0.022 |
| Ann Arbor stage | 5.418 (0.728–40.337) | 0.099 | – | – |
| Previous chemotherapy | 3.515 (0.820–15.060) | 0.090 | – | – |
| IPI score | 0.913 (0.387–2.153) | 0.835 | – | – |
| Extralodal sites | 1.401 (0.590–3.329) | 0.445 | – | – |
| LDH | 0.472 (0.190–1.176) | 0.107 | – | – |
| β2 microglobulin | 0.679 (0.230–2.007) | 0.484 | – | – |
| B symptoms | 0.899 (0.353–2.287) | 0.822 | – | – |

| Table 5 | Analysis of prognostic factors affecting OS | Various | Univariate analysis | Multivariate analysis |
| --- | --- | --- | --- | --- |
| | | HR (95% CI) | P | HR (95% CI) | P |
| Gender | 0795 (0.295–2.139) | 0.650 | – | – |
| Age | 0.390 (0.132–1.147) | 0.087 | – | – |
| ECOG | 4.149 (1.178–14.608) | 0.027 | 3.883 (1.101–13.694) | 0.035 |
| Ki-67 | 1.041 (0.135–8.027) | 0.969 | – | – |
| COO subtype | 0.153 (0.040–0.581) | 0.006 | 0.175 (0.064–0.665) | 0.010 |
| Ann Arbor stage | 3.700 (0.487–28.109) | 0.206 | – | – |
| Previous chemotherapy | 2.265 (0.514–9.988) | 0.280 | – | – |
| IPI score | 1.322 (0.357–3.586) | 0.258 | – | – |
| Extralodal sites | 0.915 (0.339–2.469) | 0.861 | – | – |
| LDH | 0.831 (0.217–3.560) | 0.674 | – | – |
| β2 microglobulin | 0.484 (0.110–2.138) | 0.338 | – | – |
| B symptoms | 1.246 (0.444–3.500) | 0.676 | – | – |
ORR of non-GCB DLBCL patients was 65% (CR: 41%). The result indicates that Ibrutinib + lenalidomide + R showed better activity and controllable safety in patients with RR DLBCL (especially non-GCB DLBCL). Surprisingly, in our retrospective study, there were 10 patients with Ibrutinib + lenalidomide + R regimen, and their ORR reached 60.0%. There were 7 patients with non-GCB DLBCL and the ORR achieved 71.4% (3 patients achieved CR; 2 patients achieved PR). For the Ibrutinib + lenalidomide + R regimen, relevant reports should continue to be collected, the number of cases should be appropriately expanded to reduce the experimental error. Although the number of cases in Ibrutinib + lenalidomide ± R group was small, the median PFS and OS were not reached during the follow-up period, indicating that the long-term treatment effect may be better than Ibrutinib ± R group. In the later period, we will expand the number of cases in the Ibrutinib + lenalidomide ± R group, extend the follow-up time, and observe the efficacy.

Michael Crump [33] mentioned that the results of the study of patients with refractory DLBCL after failure of second-line treatment or patients who relapsed after ASCT showed that their clinical prognosis was poor (The median OS was 5 months and 8–10 months, respectively). For patients with refractory DLBCL, the ORR to the next-line treatment was 26% (The CR rate was 7%), and the median OS was 6.3 months. The results of this study are better than this one. Programmed death receptor-1 antibodies, tyrosine kinase inhibitors, anti-CD79B antibody–drug conjugates, PIK3 inhibitors, and BCL-2 inhibitors are all used in the treatment of RR DLBCL. These single drugs have multiple ORRs. The ORR of these single drugs is mostly between 10–60% [10].

Compared with other treatment regimens for RR DLBCL, ORR in the Ibrutinib ± R group did not achieve the expected effect, while Ibrutinib + Lenalidomide ± R group showed better efficacy. Again, it was shown that the combined treatment of Ibrutinib was more effective than the single treatment.

Conclusion

Our study showed that the application of Ibrutinib to patients with RR DLBCL has good short-term efficacy, and the adverse reactions can be tolerated. Combined therapy was more effective than single therapy. Therefore, the appropriate drug combination therapy should be selected on the premise of paying attention to the side effects. In the near future, whether Ibrutinib combined with other drugs can play a greater potential in the treatment of RR DLBCL deserves more in-depth study in the future.

Acknowledgements We are indebted to the Lymphoma Diagnosis and Treatment Center of Henan Province for providing assistance. We also thank all the patients for allowing us to analyze their data. This study was supported by the National Natural Science Foundation of China (Grant Number 81570204).

Authors’ Contributions L.R., L.L. contributed to the conception of the study; L.R., L.L. performed the data analyses and wrote the manuscript; M.Z. helped perform the analysis with constructive discussions; All authors contributed to the writing and revisions.

Funding This study was supported by the National Natural Science Foundation of China (Grant Number 81570204).

Declarations

Conflict of interest The author reports no conflicts of interest in this work.

Ethics Approval (Include Appropriate Approvals or Waivers) This trial was in agreement with the Declaration of Helsinki. And the trial was reviewed and approved by the ethics committee of the First Affiliated Hospital of Zhengzhou University. The subjects and their families had informed consent and signed an informed consent form before their participation.

 Consent to Participate (Include Appropriate Statements) The subjects and their families had informed consent and signed an informed consent form before their participation.

Consent for publication (Include Appropriate Statements) All authors agree to publish, and there is no conflict of interest.

Availability of Data and Material (Data Transparency) All data and materials are true and valid. All tables and figures are original.

Code Availability (Software Application or Custom Code) SPSS 24.0 statistical software.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Ansell SM, Minnema MC, Johnson P et al (2019) Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study. J Clin Oncol 37(6):481–489
2. Teras LR, Desantis CE, Cerhan JR et al (2016) 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 66(6):443–459
3. Ruppert AS, Dixon JG, Salles G et al (2020) International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. J Blood Dis 135(23):2041–2048
4. He Y, Li J, Ding N et al (2019) Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma. J Exp Clin Cancer Res 38(1):86
5. Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769):503–511
6. Iacoboni G, Zucca E, Ghielmini M et al (2018) Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review. Ann Oncol 29(5):1120–1129
7. Hou K, Yu Z, Jia Y et al (2020) Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: a single-arm meta-analysis. Crit Rev Oncol Hematol 152:103010
8. Carpio C, Bouabdallah R, Ysebaert L et al (2020) Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier. Blood 135(13):996–1007
9. Coiffier B, Thieblemont C, Van Den Neste E et al (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Group d’Etudes des Lymphomes de l’Adulte. Blood 116(12):2040–2045
10. Ma X, Li L, Zhang L et al (2020) Apatinib in patients with relapsed or refractory diffuse large B cell lymphoma: a phase II, open-label, single-arm, prospective study. Drug Des Devel Ther 14:275–284
11. Sarkozy C, Sehn LH (2018) New treatment option for relapsed or refractory diffuse large B-cell lymphoma: a critical review. Best Pract Res Clin Haematol 31(3):209–216
12. Brudno JN, Kochenderfer JN (2018) Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol 15(1):31–46
13. Chow VA, Shadman M, Gopal AK (2018) Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Blood 132(8):777–781
14. Turtle CJ, Hanafi LA, Berger C et al (2019) Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+/CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med 8(355):355r
15. Gourd E (2019) New treatment option for relapsed or refractory DLBCL. Lancet Oncol 20(12):e670
16. Smith MR (2015) Ibrutinib in B lymphoid malignancies. Expert Opin Pharmacother 16(12):1879–1887
17. Pal SS, Dammajer F, Hendriks RW (2018) Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer Ther 17(1):57
18. Haselmayer P, Camps M, Liu-Bujalski L et al (2019) Efficacy and pharmacodynamic modeling of the BTK inhibitor evobrutinib in autoimmune disease models. J Immunol 202(10):2888–2906
19. Lee CS, Rattu MA, Kim SS (2016) A review of a novel, Bruton’s tyrosine kinase inhibitor, ibrutinib. J Oncol Pharm Pract 22(1):92–104
20. Qin Y, Zhao FY, Zhou Y et al (2020) Programmed cell death-1 inhibitor combined with rituximab in refractory or relapsed diffuse large B-cell lymphoma: a preliminary efficacy and safety analysis. Zhonghua Zhong Liu Za Zhi 42(12):1034–1039
21. Franke NE, Blok GJ, Voll ML et al (2020) Transient hepatotoxicity induced by vinblastine in a young girl with chiasmatic low grade glioma. Curr Drug Saf 15(3):231–235
22. Berglof A, Hamasya M, Meinke S et al (2015) Targets for ibrutinib beyond B cell malignancies. Scand J Immunol 82(3):208–217
23. Yang Y, Shaffer AR, Emre NC et al (2012) Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21(6):723–737
24. Jiang S, Qin Y, Gui L et al (2020) Genomic alterations and MYD88(MUT) variant mapping in patients with diffuse large B-cell lymphoma and response to ibrutinib. Target Oncol 15(2):221–230
25. Paydas S (2019) Management of adverse effects/toxicity of ibrutinib. Crit Rev Oncol Hematol 136:56–63
26. Bhatti M, Ayton S, Michail O et al (2019) Effect of Bruton’s tyrosine kinase inhibitors on platelet aggregation in patients with acute myocardial infarction. Thromb Res 179:64–68
27. Salem JE, Manouchehri A, Breteague M et al (2019) Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol 74(13):1667–1678
28. Brown JR, Moslehi J, O’Brien S et al (2017) Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica 102(10):1796–1805
29. Varughese T, Taur Y, Cohen N et al (2018) Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer. Clin Infect Dis 67(5):687–692
30. Yun S, Vincelette ND, Acharya U et al (2017) Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials. Clin Lymphoma Myeloma Leuk 17(1):31–37
31. Reddy NM, Thieblemont C (2017) Maintenance therapy following induction chemomunotherapy in patients with diffuse large B-cell lymphoma: current perspective. Ann Oncol 28(11):2680–2690
32. Goy A, Ramchandren R, Ghosh N et al (2019) Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center DLBCL. Blood 134(13):1024–1036
33. Crump M, Neelapu SS, Farooq U et al (2017) Outcomes in relapsed or refractory diffuse large B-cell lymphoma. Lancet Oncol 20(12):e670
Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.